Poxel receives Chinese patent for use of Imeglimin for type-2 diabetic patients with renal impairment: Lyon, France Wednesday, January 22, 2025, 18:00 Hrs [IST] Poxel SA, a clinic ...
The timing of FDA approval aligns well with the Q4 2024 publication by MediBeacon’s Chief Scientific Officer, Dr. Richard Dorshow, et al. in Kidney International with data that supports the utility of ...